ADA 2026 Standards: New Guidance Across Cardiorenal, HFpEF, and MASH in Diabetes Care

The 2026 ADA Standards update guidance on incretin-based and cardiorenal-protective therapy and add detailed new recommendations for HFpEF, MASH, and posttransplantation diabetes.

📅 Journal publication: Jan 1, 2026 · Last updated: Oct 12, 2026

ADA Standards of Care in Diabetes 2026American Diabetes Associationtype 2 diabetestype 1 diabetesGLP-1 receptor agonistsdual GIP/GLP-1 RASGLT2 inhibitorsinsulinDPP-4 inhibitorsmetformin Endocrinology / Obesity

Background Information

Understand the latest ADA guidelines for diabetes medication management in 2026.

The ADA Standards of Care offer updated guidelines on pharmacological management of diabetes, impacting therapy choices. New recommendations focus on individualized treatment plans, emphasizing cardiovascular risk reduction alongside glycemic control. Pharmacists should adapt patient counseling and medication management to align with the latest standard of care recommendations. Stay current with ADA 2026 guidelines to optimize diabetes management and patient outcomes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: American Diabetes Association Professional Practice Committee for Diabetes*

Citation: American Diabetes Association Professional Practice Committee for Diabetes* 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes care. 2026;49(Suppl 1):S183-S215. doi:10.2337/dc26-S009

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →